← Back to all trials
Suspended
NCT07146113
Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation
Conditions: Prostate Cancer
Sex: Male
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 400
Sponsor: AstraZeneca
Location: Research Site Arkhangelsk
Summary
A multicentre observational study on treatment approaches and biomarkers in de novo metastatic hormone sensitive prostate cancer in Russian Federation
Eligibility Criteria
Inclusion Criteria:
1. Male patients aged ≥ 18 years old;
2. Signed ICF, including consent for FFPE tumor tissue sample testing;
3. De novo histologically confirmed high-aggressive (Gleason 8-10) mPC;
4. Diagnosis of mPC (metastatic prostate cancer) within 2 years prior to inclusion;
5. Availability of source medical documentation;
6. Presence of biopsy FFPE tumor tissue sample, obtained as part of standard clinical practice, which will be used for biomarker testing;
7. Unknown HRRm status.
Exclusion Criteria:
1\. Participation in any interventional trial since the mPC diagnosis.
Source: ClinicalTrials.gov (NCT07146113). StuddyBuddy aggregates publicly available trial information.
